Enrolling trials: Fred Hutchinson Cancer Center at Overlake
Contact: Luat Le |lle@seattlecca.org | 206-606-4191
Note: If you are having trouble viewing on a phone download a pdf here
GI CANCER ENROLLING TRIALS
| Protocol name and PI | Indication/Eligibility |
|
| Hockenbery +1 year
Study PI: David Hockenbery Local PI: Jason Comer |
Treatment naïve, colorectal cancer, any stage
-no ab, probiotic use |
Features of Gut Microbiome Promoting Colorectal Cancers in Different Risk Groups
-Biorepository: stool sample collection study |
| EA2186 GIANT
PI: David Zhen Local PI: Jason Comer |
Metastatic
pancreatic cancer -70 years or older |
A Randomized Phase II Study of Gemcitabine and NabPaclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT) |
| ColoCare,
Consortium PI: William Grady, Christopher Li, Fred Hutch |
Colorectal Cancer, any stage
-allows ab, probiotic use -diagnosed w/in past 12 months -intact primary |
Discovery and verification of novel biomarkers of colorectal cancer recurrence
-Biorepository: blood sample collection |
Updated 10/07/2022
GU CANCER ENROLLING TRIALS
| Protocol name and PI | Indication/Eligibility | Protocol title |
| PROMISE
PI: Heather Cheng, SLU |
Any prostate cancer | PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
-Free color genomics testing |
| S1802
PI: Heather Cheng |
Metastatic Prostate Cancer
-no more than 28 weeks of SST, brain mets ineligible, requires urology consult |
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer |
| CASPAR A031902
Consortium PI:
|
Metastatic
Castration Resistant Prostate Cancer -archival tissue available, no prior enzalutamide |
A Phase III Trial of Enzulatamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer |
Updated 10/07/2022
MALIGNANT HEME ENROLLING TRIALS
| Protocol name and PI | Indication/Eligibility | Protocol title |
| S1925 EVOLVE
Consortium PI: Mazyar Shadman Local PI: Jason Comer |
Newly diagnosed asymptomatic high risk patients with chronic lymphocytic lymphoma/small lymphocytic
lymphoma -diagnosed w/in past 12 months |
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study |
| S1918
Consortium PI: Paul Martin Local PI: Jason Comer |
Older patients with DLBCL, transformed lymphoma, high
grade lymphoma w MYC and BCL2 and/or BCL6 rearrangements -75 years or older |
A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements |
Updated 10/07/2022
LUNG CANCER ENROLLING TRIALS
| Protocol name and PI | Indication/Eligibility | Protocol title |
| EA5181
Consortium PI: Dan Moore Local PI: Jason Comer |
First line:
Unresectable stage III (A/B/C) NSCLC or nodal recurrence after surgery for early stage NSCLC -PFTs required for screening |
Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Chemo options: -Cisplatin/Etoposide -Pemetrexed/Cisplatin (non-squamous histology only) -Paclitaxel/Carboplatin |
BREAST CANCER ENROLLING TRIALS
| Protocol name and PI | Indication/Eligibility | Protocol title |
| Breast Repository
Study PI: Eileen Consorti |
Any Overlake Breast cancer patients or breast patients
interested in the study |
Breast Repository Study at Overlake |
Updated 10/07/2022